Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

Caroline Irene Piatek, M.D., Maria E. Vergara-Lluri, M.D., Vinod Pullarkat, MD, Imran N. Siddiqi, M.D, Ph.D., Casey O'Connell, MD, Donald I. Feinstein, MD, Russell K. Brynes, MD

Blood (2013) 122 (21): 3714.

https://doi.org/10.1182/blood.V122.21.3714.3714

Published: 2013

Journal Articles

TEMPI: A Reversible Syndrome Following Treatment with Bortezomib

Wilfried A. Schroyens, MD, PhD, Casey L. O'Connell, MD, Martha Q Lacy, MD, Eyal C. Attar, MD, Noopur Raje, MD, Bradley G. Somer, MD, Flavia G Rosado, MD, James Hoyer, MD, Donald I. Feinstein, MD, David B. Sykes, MD, PhD

Blood (2012) 120 (21): 986.

https://doi.org/10.1182/blood.V120.21.986.986

Published: 2012

Journal Articles

The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting

David B. Sykes, MD, PhD, Wilfried A. Schroyens, MD, PhD, Casey L. O'Connell, MD, Donald I. Feinstein, MD, Hasan Bazari, MD, Douglas M. Dahl, MD, Robert B. Colvin, MD, Bernard P. Paelinck, MD, PhD, Raul N. Uppot, MD, Bart Op de Beeck, MD, William Boswell, MD, Noopur S. Raje, MD, Nancy Lee Harris, MD, Eyal C. Attar, MD

Blood (2011) 118 (21): 1037.

https://doi.org/10.1182/blood.V118.21.1037.1037

Published: 2011

Journal Articles

A Fatal Bleeding Disorder Due to Antibody Mediated Acquired Factor X and Prothrombin Deficiency.

Leanne Rochanda, BA, Donald I. Feinstein, MD, Gregory J. del Zoppo, MD, Howard A. Liebman, MD

Blood (2006) 108 (11): 4072.

https://doi.org/10.1182/blood.V108.11.4072.4072

Published: 2006

Journal Articles

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Alexandra M. Levine, MD, Anil Tulpule, MD, Lynne Smith, PhD, Byron M. Espina, AB, Ann F. Mohrbacher, MD, Donald I. Feinstein, MD

Blood (2005) 106 (11): 945.

https://doi.org/10.1182/blood.V106.11.945.945

Published: 2005

NARROW

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

TEMPI: A Reversible Syndrome Following Treatment with Bortezomib

The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting

A Fatal Bleeding Disorder Due to Antibody Mediated Acquired Factor X and Prothrombin Deficiency.

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

TEMPI: A Reversible Syndrome Following Treatment with Bortezomib

The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting

A Fatal Bleeding Disorder Due to Antibody Mediated Acquired Factor X and Prothrombin Deficiency.

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only